Pub Date : 2025-01-10DOI: 10.1016/s1473-3099(25)00012-x
Bipin Adhikari, Shiva Raj Mishra
No Abstract
{"title":"Engaging pose and gaze in global health research","authors":"Bipin Adhikari, Shiva Raj Mishra","doi":"10.1016/s1473-3099(25)00012-x","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00012-x","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"39 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142961852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-09DOI: 10.1016/s1473-3099(24)00741-2
El-hadji Konko Ciré Ba, Michelle E Roh, Abdoulaye Diallo, Tidiane Gadiaga, Amadou Seck, Sylla Thiam, Ari Fogelson, Seynabou Gaye, Ibrahima Diallo, Aminata Colle Lo, Elhadji Diouf, Oumar Gallo Ba, Alioune Badara Gueye, Xue Wu, Paul Milligan, Tabitha Kibuka, Moustapha Hama, Erin Eckert, Julie Thwing, Adam Bennett, Jean Louis Ndiaye
<h3>Background</h3>In Africa, the scale-up of malaria-control interventions has reduced malaria burden, but progress towards elimination has stalled. Mass drug administration (MDA) is promising as a transmission-reducing strategy, but evidence from low-to-moderate transmission settings is needed. We aimed to assess the safety, coverage, and effect of three cycles of MDA with dihydroartemisinin–piperaquine plus single, low-dose primaquine on <em>Plasmodium falciparum</em> incidence and prevalence in southeast Senegal.<h3>Methods</h3>We conducted a two-arm, open-label, cluster-randomised controlled trial in villages in the Tambacounda health district of southeast Senegal. Eligible villages had a population size of 200–800, were within a health-post catchment area with an annual malaria incidence of 60–160 cases per 1000 people, and had an established or planned Prise en Charge à Domicile Plus model. We randomly assigned villages (1:1) using a stratified, constrained randomisation approach to receive either three cycles of MDA with oral dihydroartemisinin–piperaquine plus single, low-dose primaquine administered at 6-week intervals (intervention) or to standard of care, which included three cycles of seasonal malaria chemoprevention (SMC) with oral sulfadoxine–pyrimethamine plus amodiaquine administered at 4-week intervals (control). Participants, the field team, and all investigators, including those who assessed outcomes and analysed data, were unmasked to allocation assignment. Laboratory technicians were masked to intervention assignment. The primary outcome was village-level, <em>P falciparum</em>-confirmed malaria incidence in the post-intervention year (ie, July to December, 2022). Secondary outcomes included malaria incidence during the intervention year (ie, July to December, 2021), coverage and safety of MDA, and adverse events. We conducted analyses using an intention-to-treat approach. The trial is registered with <span><span>ClinicalTrials.gov</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span> (<span><span>NCT04864444</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span>) and is completed.<h3>Findings</h3>Between Sept 1 and Oct 25, 2020, 523 villages were geolocated and screened for eligibility; 111 met the inclusion criteria. Of these, 60 villages were randomly selected and assigned to the intervention arm or control arm. Distribution coverage of all three doses of dihydroartemisinin–piperaquine was 6057 (73·6%) of 8229 participants in the first cycle, 6836 (78·8%) of 8673 participants in the second cycle, and 7065 (81·3%) of 8690 participants in the third cycle. Distribution coverage of single, low-dose primaquine was 628
{"title":"Effect of mass drug administration on malaria incidence in southeast Senegal during 2020–22: a two-arm, open-label, cluster-randomised controlled trial","authors":"El-hadji Konko Ciré Ba, Michelle E Roh, Abdoulaye Diallo, Tidiane Gadiaga, Amadou Seck, Sylla Thiam, Ari Fogelson, Seynabou Gaye, Ibrahima Diallo, Aminata Colle Lo, Elhadji Diouf, Oumar Gallo Ba, Alioune Badara Gueye, Xue Wu, Paul Milligan, Tabitha Kibuka, Moustapha Hama, Erin Eckert, Julie Thwing, Adam Bennett, Jean Louis Ndiaye","doi":"10.1016/s1473-3099(24)00741-2","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00741-2","url":null,"abstract":"<h3>Background</h3>In Africa, the scale-up of malaria-control interventions has reduced malaria burden, but progress towards elimination has stalled. Mass drug administration (MDA) is promising as a transmission-reducing strategy, but evidence from low-to-moderate transmission settings is needed. We aimed to assess the safety, coverage, and effect of three cycles of MDA with dihydroartemisinin–piperaquine plus single, low-dose primaquine on <em>Plasmodium falciparum</em> incidence and prevalence in southeast Senegal.<h3>Methods</h3>We conducted a two-arm, open-label, cluster-randomised controlled trial in villages in the Tambacounda health district of southeast Senegal. Eligible villages had a population size of 200–800, were within a health-post catchment area with an annual malaria incidence of 60–160 cases per 1000 people, and had an established or planned Prise en Charge à Domicile Plus model. We randomly assigned villages (1:1) using a stratified, constrained randomisation approach to receive either three cycles of MDA with oral dihydroartemisinin–piperaquine plus single, low-dose primaquine administered at 6-week intervals (intervention) or to standard of care, which included three cycles of seasonal malaria chemoprevention (SMC) with oral sulfadoxine–pyrimethamine plus amodiaquine administered at 4-week intervals (control). Participants, the field team, and all investigators, including those who assessed outcomes and analysed data, were unmasked to allocation assignment. Laboratory technicians were masked to intervention assignment. The primary outcome was village-level, <em>P falciparum</em>-confirmed malaria incidence in the post-intervention year (ie, July to December, 2022). Secondary outcomes included malaria incidence during the intervention year (ie, July to December, 2021), coverage and safety of MDA, and adverse events. We conducted analyses using an intention-to-treat approach. The trial is registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> (<span><span>NCT04864444</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>) and is completed.<h3>Findings</h3>Between Sept 1 and Oct 25, 2020, 523 villages were geolocated and screened for eligibility; 111 met the inclusion criteria. Of these, 60 villages were randomly selected and assigned to the intervention arm or control arm. Distribution coverage of all three doses of dihydroartemisinin–piperaquine was 6057 (73·6%) of 8229 participants in the first cycle, 6836 (78·8%) of 8673 participants in the second cycle, and 7065 (81·3%) of 8690 participants in the third cycle. Distribution coverage of single, low-dose primaquine was 628","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"58 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142939530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-09DOI: 10.1016/s1473-3099(24)00764-3
Lorenz von Seidlein
No Abstract
{"title":"Another antimalarial mass drug administration?","authors":"Lorenz von Seidlein","doi":"10.1016/s1473-3099(24)00764-3","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00764-3","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"24 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142939508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-08DOI: 10.1016/s1473-3099(24)00657-1
Robin C Nesbitt, Vincent Kinya Asilaza, Catia Alvarez, Priscillah Gitahi, Patrick Nkemenang, Jetske Duncker, Melat Haile, Primitive Gakima, Joseph F Wamala, Fredrick Beden Loro, Aybüke Koyuncu, Duol Biem, Manuel Albela, Monica Rull, Etienne Gignoux, John Rumunu, Isabella Eckerle, Iza Ciglenecki, Andrew S Azman
Background
Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis, particularly in Asia and Africa, where HEV genotypes 1 and 2 are prevalent. Although a recombinant vaccine, Hecolin, is available, it has not been used to control outbreaks. The licensed three-dose regimen might pose challenges for it to be an impactful outbreak control tool. Our study aimed to estimate the effectiveness of two doses of Hecolin in the context of the first-ever reactive use of the vaccine.
Methods
We conducted a case–control study during an HEV outbreak in the Bentiu internally displaced persons camp, South Sudan. Patients with acute jaundice syndrome (suspected cases) seeking care at the Médecins Sans Frontières hospital were screened for study eligibility. Eligible participants were those that had been eligible for vaccination (ie, living in the camp and aged 16–40 years). Confirmed cases were defined as individuals who tested positive for hepatitis E by RT-PCR or anti-HEV IgM ELISA. Each case was matched to six controls by age, sex, pregnancy status, and residence. Self-reported vaccination status was verified through vaccination cards. The primary analysis was two-dose vaccine effectiveness, which we estimated with a matched case–control design using conditional logistic regression models. In secondary analyses we estimated vaccine effectiveness using a test-negative design and the screening method. We used test-negative cases and their matched controls as a bias indicator analysis to help quantify potential health seeking behaviour biases.
Findings
Between May 10 and Dec 30, 2022, we identified 859 patients with suspected hepatitis E. Of these, 201 met the eligibility criteria and 21 cases had laboratory confirmed hepatitis E. Among the confirmed cases, 10 (48%) were unvaccinated compared with 33 (27%) of 121 matched controls. In the primary analysis we estimated an unadjusted two-dose vaccine effectiveness of 67·8% (95% CI –28·6 to 91·9), and a two-dose vaccine effectiveness of 84·0% (–208·5 to 99·2) after adjustment for potential confounders. The bias indicator analysis suggested that test-negative cases might have been more likely to have been vaccinated than their matched community controls due to different health-care seeking behaviours, potentially meaning underestimation of effectiveness estimates. The test-negative design, which uses facility-matched controls, led to an adjusted two-dose effectiveness of 89·4% (56·4 to 98·0).
Interpretation
Despite the small sample size, our estimates provide evidence of effectiveness of a two-dose regimen against HEV genotype 1 during a protracted outbreak, supporting its use in similar contexts.
Funding
Médecins Sans Frontières.
{"title":"The effectiveness of two doses of recombinant hepatitis E vaccine in response to an outbreak in Bentiu, South Sudan: a case–control and bias indicator study","authors":"Robin C Nesbitt, Vincent Kinya Asilaza, Catia Alvarez, Priscillah Gitahi, Patrick Nkemenang, Jetske Duncker, Melat Haile, Primitive Gakima, Joseph F Wamala, Fredrick Beden Loro, Aybüke Koyuncu, Duol Biem, Manuel Albela, Monica Rull, Etienne Gignoux, John Rumunu, Isabella Eckerle, Iza Ciglenecki, Andrew S Azman","doi":"10.1016/s1473-3099(24)00657-1","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00657-1","url":null,"abstract":"<h3>Background</h3>Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis, particularly in Asia and Africa, where HEV genotypes 1 and 2 are prevalent. Although a recombinant vaccine, Hecolin, is available, it has not been used to control outbreaks. The licensed three-dose regimen might pose challenges for it to be an impactful outbreak control tool. Our study aimed to estimate the effectiveness of two doses of Hecolin in the context of the first-ever reactive use of the vaccine.<h3>Methods</h3>We conducted a case–control study during an HEV outbreak in the Bentiu internally displaced persons camp, South Sudan. Patients with acute jaundice syndrome (suspected cases) seeking care at the Médecins Sans Frontières hospital were screened for study eligibility. Eligible participants were those that had been eligible for vaccination (ie, living in the camp and aged 16–40 years). Confirmed cases were defined as individuals who tested positive for hepatitis E by RT-PCR or anti-HEV IgM ELISA. Each case was matched to six controls by age, sex, pregnancy status, and residence. Self-reported vaccination status was verified through vaccination cards. The primary analysis was two-dose vaccine effectiveness, which we estimated with a matched case–control design using conditional logistic regression models. In secondary analyses we estimated vaccine effectiveness using a test-negative design and the screening method. We used test-negative cases and their matched controls as a bias indicator analysis to help quantify potential health seeking behaviour biases.<h3>Findings</h3>Between May 10 and Dec 30, 2022, we identified 859 patients with suspected hepatitis E. Of these, 201 met the eligibility criteria and 21 cases had laboratory confirmed hepatitis E. Among the confirmed cases, 10 (48%) were unvaccinated compared with 33 (27%) of 121 matched controls. In the primary analysis we estimated an unadjusted two-dose vaccine effectiveness of 67·8% (95% CI –28·6 to 91·9), and a two-dose vaccine effectiveness of 84·0% (–208·5 to 99·2) after adjustment for potential confounders. The bias indicator analysis suggested that test-negative cases might have been more likely to have been vaccinated than their matched community controls due to different health-care seeking behaviours, potentially meaning underestimation of effectiveness estimates. The test-negative design, which uses facility-matched controls, led to an adjusted two-dose effectiveness of 89·4% (56·4 to 98·0).<h3>Interpretation</h3>Despite the small sample size, our estimates provide evidence of effectiveness of a two-dose regimen against HEV genotype 1 during a protracted outbreak, supporting its use in similar contexts.<h3>Funding</h3>Médecins Sans Frontières.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"20 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142936828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-08DOI: 10.1016/s1473-3099(24)00686-8
Chunlan Zhuang, Ting Wu, Jun Zhang, Ningshao Xia
No Abstract
{"title":"Hecolin vaccination strategies for hepatitis E outbreak control in resource-constrained settings","authors":"Chunlan Zhuang, Ting Wu, Jun Zhang, Ningshao Xia","doi":"10.1016/s1473-3099(24)00686-8","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00686-8","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"6 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142936830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-08DOI: 10.1016/s1473-3099(24)00719-9
Matthew E Coldiron, Issaka Soumana, Elisabeth Baudin, Céline Langendorf, Corinne Mamiafo Tchoula, Souleymane Brah, Angela Karani, Katherine E Gallagher, E Wangeci Kagucia, J Anthony G Scott, Rebecca F Grais
<h3>Background</h3>In settings with low pneumococcal conjugate vaccine (PCV) coverage, multi-age cohort mass campaigns could increase population immunity, and fractional dosing could increase affordability. We aimed to evaluate the effect of mass campaigns on nasopharyngeal pneumococcal carriage of Pneumosil (PCV10) in children aged 1–9 years in Niger.<h3>Methods</h3>In this three-arm, open-label, cluster-randomised trial, 63 clusters of one to four villages in Niger were randomly assigned (3:3:1) using block randomisation to receive campaigns consisting of a single full dose of a 10-valent PCV (Pneumosil), a single one-fifth dose of Pneumosil, or no campaign. Independently sampled carriage surveys were done among 2268 households 6 months before and after vaccination, collecting nasopharyngeal swabs from healthy children for culture and serotyping; those with contraindication to nasopharyngeal swabbing were excluded. The primary outcome was nasopharyngeal carriage of vaccine-serotype pneumococcus. We tested whether vaccine-type carriage was reduced in full-dose versus control clusters; and whether fractional doses were non-inferior to full-doses (lower bound 95% CI more than –7·5%), using generalised estimating equations to analyse cluster summaries at baseline and follow-up, controlling for covariates to estimate risk differences and their 95% CIs. The study is registered with <span><span>ClinicalTrials.gov</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span> (<span><span>NCT05175014</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span>) and the Pan-African Clinical Trials Registry (PACTR20211257448484).<h3>Findings</h3>Surveys were done between Dec 22, 2021, and March 18, 2022, and between Dec 12, 2022, and March 9, 2023. The vaccination campaign ran from June 15 to Aug 2, 2022. Participants' characteristics were consistent across surveys and groups. Pre-vaccination, vaccine-type carriage was 15·6% (149 of 955 participants) in the full-dose group, 17·9% (170 of 948) in the fractional-dose group, and 18·8% (60 of 320) in the control group. Post-vaccination, vaccine-type carriage was 4·6% (44 of 967) in the full-dose group, 8·0% (77 of 962) in the fractional-dose group, and 16·5% (53 of 321) in the control group. The primary analysis showed a risk difference of –16·2% (95% CI –28·6 to –3·0) between the full-dose group and control group (p=0·002 for superiority), and –3·8% (–6·1 to –1·6) between the full-dose group and fractional-dose group, meeting the non-inferiority criteria. No adverse events were judged to be related to vaccination.<h3>Interpretation</h3>Multi-age cohort campaigns had a marked effect on vaccine-type carriage and fr
{"title":"Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluster-randomised trial","authors":"Matthew E Coldiron, Issaka Soumana, Elisabeth Baudin, Céline Langendorf, Corinne Mamiafo Tchoula, Souleymane Brah, Angela Karani, Katherine E Gallagher, E Wangeci Kagucia, J Anthony G Scott, Rebecca F Grais","doi":"10.1016/s1473-3099(24)00719-9","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00719-9","url":null,"abstract":"<h3>Background</h3>In settings with low pneumococcal conjugate vaccine (PCV) coverage, multi-age cohort mass campaigns could increase population immunity, and fractional dosing could increase affordability. We aimed to evaluate the effect of mass campaigns on nasopharyngeal pneumococcal carriage of Pneumosil (PCV10) in children aged 1–9 years in Niger.<h3>Methods</h3>In this three-arm, open-label, cluster-randomised trial, 63 clusters of one to four villages in Niger were randomly assigned (3:3:1) using block randomisation to receive campaigns consisting of a single full dose of a 10-valent PCV (Pneumosil), a single one-fifth dose of Pneumosil, or no campaign. Independently sampled carriage surveys were done among 2268 households 6 months before and after vaccination, collecting nasopharyngeal swabs from healthy children for culture and serotyping; those with contraindication to nasopharyngeal swabbing were excluded. The primary outcome was nasopharyngeal carriage of vaccine-serotype pneumococcus. We tested whether vaccine-type carriage was reduced in full-dose versus control clusters; and whether fractional doses were non-inferior to full-doses (lower bound 95% CI more than –7·5%), using generalised estimating equations to analyse cluster summaries at baseline and follow-up, controlling for covariates to estimate risk differences and their 95% CIs. The study is registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> (<span><span>NCT05175014</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>) and the Pan-African Clinical Trials Registry (PACTR20211257448484).<h3>Findings</h3>Surveys were done between Dec 22, 2021, and March 18, 2022, and between Dec 12, 2022, and March 9, 2023. The vaccination campaign ran from June 15 to Aug 2, 2022. Participants' characteristics were consistent across surveys and groups. Pre-vaccination, vaccine-type carriage was 15·6% (149 of 955 participants) in the full-dose group, 17·9% (170 of 948) in the fractional-dose group, and 18·8% (60 of 320) in the control group. Post-vaccination, vaccine-type carriage was 4·6% (44 of 967) in the full-dose group, 8·0% (77 of 962) in the fractional-dose group, and 16·5% (53 of 321) in the control group. The primary analysis showed a risk difference of –16·2% (95% CI –28·6 to –3·0) between the full-dose group and control group (p=0·002 for superiority), and –3·8% (–6·1 to –1·6) between the full-dose group and fractional-dose group, meeting the non-inferiority criteria. No adverse events were judged to be related to vaccination.<h3>Interpretation</h3>Multi-age cohort campaigns had a marked effect on vaccine-type carriage and fr","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"35 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142936893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-08DOI: 10.1016/s1473-3099(24)00768-0
Fiona M Russell, Kim Mulholland, Leith Greenslade
No Abstract
{"title":"Mass doses of fractional pneumococcal vaccine in humanitarian settings","authors":"Fiona M Russell, Kim Mulholland, Leith Greenslade","doi":"10.1016/s1473-3099(24)00768-0","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00768-0","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"85 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142937005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-08DOI: 10.1016/s1473-3099(25)00004-0
Shields RK, Abbo LM, Ackley R, et al. Effectiveness of ceftazidime–avibactam versus ceftolozanetazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study. Lancet Infect Dis 2024; published online Dec 16. https://doi.org/10.1016/S1473-3099(24)00648-0—In this Article, the denominator for patients treated with ceftazidime–avibactam in the second sentence of the final paragraph of the Results section should have been 177. This correction has been made to the online version as of Jan 8, 2025.
{"title":"Correction to Lancet Infect Dis 2024; published online Dec 16. https://doi.org/10.1016/S1473-3099(24)00648-0","authors":"","doi":"10.1016/s1473-3099(25)00004-0","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00004-0","url":null,"abstract":"<em>Shields RK, Abbo LM, Ackley R, et al. Effectiveness of ceftazidime–avibactam versus ceftolozanetazobactam for multidrug-resistant</em> Pseudomonas aeruginosa <em>infections in the USA (CACTUS): a multicentre, retrospective, observational study.</em> Lancet Infect Dis <em>2024; published online Dec 16. https://doi.org/10.1016/S1473-3099(24)00648-0</em>—In this Article, the denominator for patients treated with ceftazidime–avibactam in the second sentence of the final paragraph of the Results section should have been 177. This correction has been made to the online version as of Jan 8, 2025.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"118 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142936831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-08DOI: 10.1016/s1473-3099(25)00006-4
Dondorp AM. MMV533, a promising new antimalarial on the horizon. Lancet Infect Dis 2024; published online Dec 18. https://doi.org/10.1016/S1473-3099(24)00730-8—In this Comment, the fourth sentence of the second paragraph should read “…at 20 mg, which is similar to other partner drugs in artemisinin-based combination therapies.” This correction has been made to the online version as of Jan 8, 2025, and will be made to the printed version.
{"title":"Correction to Lancet Infect Dis 2024; published online Dec 18. https://doi.org/10.1016/S1473-3099(24)00730-8","authors":"","doi":"10.1016/s1473-3099(25)00006-4","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00006-4","url":null,"abstract":"<em>Dondorp AM. MMV533, a promising new antimalarial on the horizon.</em> Lancet Infect Dis <em>2024; published online Dec 18. https://doi.org/10.1016/S1473-3099(24)00730-8</em>—In this Comment, the fourth sentence of the second paragraph should read “…at 20 mg, which is similar to other partner drugs in artemisinin-based combination therapies.” This correction has been made to the online version as of Jan 8, 2025, and will be made to the printed version.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"37 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142937078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：